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Abstract
The infection of the airways of cystic fibrosis patients by Pseudomonas aeruginosa is a complex, multistaged process that is
associated with a deterioration of lung function. The complexity of the formation of biofilms and their interaction with the
immune system means that treatment with antibiotics has been an uncertain science. Tobramycin nebuliser solution (TNS) is a
novel formulation of the antibiotic tobramycin developed specifically for inhalation. A recent large trial comparing TNS with
inhaled colistin provided an opportunity to define further the effect of antibiotic treatment on microbial infection. In the TNS
group, the percentage of patients with a tobramycin minimal inhibitory concentration (MIC) 04 mg l increased from 38 toy1
49%, and the percentage of patients with a colistin MIC04 mg l remained at 55%. In the colistin group, the percentage ofy1
patients with a colistin MIC04 mg l remained at 34%, whereas the percentage of patients with a tobramycin MIC04 mg ly1 y1
decreased from 27 to 16%. Furthermore, clinical and bacterial response to TNS and colistin was independent of the MIC at
baseline. Neither antimicrobial therapy was associated with infection by Burkholderia cepacia or other inherently resistant
pathogens. We conclude that conventional measures of antimicrobial resistance may underestimate the effectiveness of tobramycin
and colistin when delivered at the high concentrations achieved with the TNS formulation.
 2002 European Cystic Fibrosis Society. Published by Elsevier Science B.V. All rights reserved.
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1. Introduction
‘The microbiology of lung disease in patients with
cystic fibrosis is a subspeciality unto itself’ w1x.
The above statement, written more than a decade ago,
applies equally to the complex (and almost unique)
relationship of Pseudomonas aeruginosa with cystic
fibrosis (CF) lung disease and to the treatment of CF
pulmonary infections. The recently completed European
TOBI trial w49x, which compared the use of inhaled
tobramycin nebuliser solution (TNS) with colistin, pro-
vided a unique opportunity to investigate aspects of
antimicrobial response and resistance in this population.
It is important to stress at the outset that the European
TOBI trial focused on the treatment of established P.
aeruginosa infection—a situation of which it has also
been said, ‘the bacteria are seldom if ever eradicated’.
To illustrate the challenge faced by clinicians and micro-
biologists in assessing antibiotic therapy in such chronic
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infections, it is necessary to summarize what is known
of the relationship between P. aeruginosa and the CF
lung.
P. aeruginosa infection of CF airways is a life-long
process involving several stages, and it provides a
striking example of bacterial adaptation w2,3x. Firstly, an
initial and often asymptomatic stage is signalled by
culture of typical nonmucoid colonial morphotypes of
P. aeruginosa. At this stage, infection may be intermit-
tent and involve different strains of P. aeruginosa.
This initial stage is characteristically followed by the
gradual emergence of mucoid variants of the colonizing
strain, a rise in antipseudomonas antibodies w4x and life-
limiting chronic infection w5,6x. The time taken for
transition varies from patient to patient, and mucoid P.
aeruginosa may be the first organism cultured from
sputum if bacteriological investigations are infrequent.
In one well-documented episode, involving primary
acquisition of P. aeruginosa from a hydrotherapy pool,
transition to mucoid occurred within 3 months w7x. In
vivo, this transition is associated with the presence of
bacterial biofilms, bronchial plugs and life-long in-
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Table 1
Microbiological issues in the antibiotic treatment of CF lung infections
Does antibiotic treatment reduce susceptibility of P. aeruginosa and prejudice further treatment?
Are high MIC values at the start of treatment associated with poor clinical outcome?
How do we define resistance in the context of CF airway infection and aerosolized antibiotics?
Do changes occur in the lung microbial flora of treated patients, e.g. superinfections with B. cepacia and other inherently resistant CF
pathogens?
tractable airway infection with the same strain of P.
aeruginosa w3,8–10x.
From the mid-1980s, a major therapeutic development
in the management of pseudomonas infection in CF
patients was the growing acceptance of initiating aggres-
sive therapy at the first sputum culture of P. aeruginosa
colonization; the aim was to clear the airways and delay
or prevent subsequent colonization w11–13x. Strategical-
ly, early and aggressive therapy makes sense. At this
stage, nonmucoid P. aeruginosa can be eradicated
w11,14–16x, and reduction in sputum bacterial density
can improve lung function w14,17x.
Reduction in the pseudomonas population will also
reduce the bacterial reservoir from which spontaneous
alginate-producing mutants of P. aeruginosa arise,
selected by their enhanced resistance to antibiotics and
phagocytes w3,8x. Recent in vitro studies reported
mucoid variants of P. aeruginosa PAO1 in biofilm
cultures grown in the presence of hydrogen peroxide;
the authors suggest that conversion to mucoid is a stress-
related response during exposure to oxygen radicals
such as would be released from pulmonary neutrophils
w18x. At high bacterial densities, cell-to-cell signalling
has also been implicated in the development of pseu-
domonas biofilms w19x. Known as ‘quorum sensing’,
this system relies on autoinducer molecules (homoserine
lactones) produced by P. aeruginosa reaching sufficient
concentrations to influence biofilm formation and other
bacterial systems.
Pseudomonas alginate is composed of the uronic acid
b-D-mannuronate and its C-5 epimer a-L-guluronate
w20x. As with algal alginates, pseudomonas alginate
readily forms gels in the presence of physiological
concentrations of Ca w21,22x. The viscosity of algin-2q
ates is also enhanced by the presence of bronchial
mucins and neutrophil DNA w23x. These properties help
to explain the large gel-like microcolonies and biofilms
seen in CF airways w23,24x and the term ‘frustrated
phagocytosis’ when pulmonary neutrophils are faced
with a large persistent target w21,25x.
Whether biofilms are formed mainly as a result of
selection of spontaneous mucoid variants, by induction
in the whole population in response to environmental
stress, or by cell-to-cell signalling remains unclear. It is
also not clear how bronchial mucins, DNA, alginate and
other bacterial polysaccharides contribute structurally to
these sessile bacterial communities. What is clear is
that, in the CF lung, biofilms would provide a complex
community of P. aeruginosa with formidable protection
against pulmonary defences and antibiotic therapy.
Having summarized the complex microbiology of P.
aeruginosa and CF lung disease, we can appreciate that
antibiotic therapy plays a major role in the management
of CF lung disease, and probably influences the striking
differences in the prevalence rates for P. aeruginosa and
other CF pathogens in patients attending different CF
centres w26x. However, the design and interpretation of
antibiotic trials, in particular those involving chronic P.
aeruginosa infection, presents formidable challenges and
differs from antibiotic use in non-CF patients w27x. Table
1 highlights other major microbiological issues associ-
ated with the use of inhaled antibiotics in the treatment
of chronic P. aeruginosa infection in CF patients.
Defining sensitivity and resistance in the context of
antibiotic therapy in CF is difficult and merits particular
attention. In non-CF infections, the term ‘resistance’ is
usually defined as failure to eradicate the bacterial
pathogen and reduce or eliminate the clinical symptoms
of infection. If these criteria are applied to established
CF lung infections caused by P. aeruginosa, then almost
all could be defined as resistant. However, if the major
end point is clinical response, then what parameters of
response are acceptable? Are serial measurements of
inflammatory markers, such as C-reactive protein, a
better way of measuring how the patients rather than
the pathogen is ‘responding’ to therapy? w28x. In a
progressive disease, such as CF, is it acceptable to
achieve short-term or long-term improvement in lung
function without eradication or even reduction in bac-
terial load? Is resistance an inevitable but acceptable
price to pay for improved lung function? Finally, in
laboratory tests, what is the appropriate sample popula-
tion on which the definition of bacterial susceptibility
and resistance is made?
The antimicrobial breakpoint at the site of infection
is typically defined as the highest level of antibiotic
which can be achieved at that site without toxicity—a
bacterial pathogen with a minimal inhibitory concentra-
tion (MIC) greater than the breakpoint is defined as
resistant. In non-CF infections, antibiotic susceptibility
is usually determined by testing one or more bacterial
colonies picked from a primary culture plate; this in
vitro sensitivity is then used to predict the likelihood of
eradicating the whole population of infecting organisms
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Table 2
Baseline demographics w1x
TNS Colistin
Number of patients 53 62
Log CFU mly1a10 6.3"1.5 6.8"1.3
Tobramycin MIC 04 mg ml , n (%)y1 b 20 (39) 31 (52)
Colistin MIC 04 mg ml , n (%)y1 c 13 (25) 19 (32)
No significant differences were detected between the groups.a
One TNS patient missing CFU.b
Two TNS and two colistin patients missing MIC.c
Table 3
Patients with highest tobramycin P. aeruginosa MIC04 mg ly1
TNS (%) Colistin (%)
(ns45) (ns47)
Baseline 38 55
Week 4 49 55
Table 4
Patients with highest colistin P. aeruginosa MIC04 mg ly1
TNS (%) Colistin (%)
(ns45) (ns47)
Baseline 27 34
Week 4 16 34
which may exceed 10 colony-forming units ml . In9 y1
many non-CF infections, the antibiotic sensitivity pat-
terns of multiple colonial samples is relatively uniform.
This is not the case in the chronically colonized CF
lung, where a range of MIC values can be observed
even if infection involves a single strain of P. aeruginosa
w14,29,30x. Furthermore, in CF, drug delivery is handi-
capped by the presence of bronchial plugs and the
location of P. aeruginosa within the protective matrix
of bacterial biofilms w3,24x. Finally, in vitro susceptibil-
ity testing is exposed to many variables; these range
from the growth state of the pathogen (log or stationary
phases), inoculum density, culture medium and whether
testing is based on antibiotic impregnated disks, agar
dilution or microbroth dilution methodologies.
1.1. Use of inhaled tobramycin and colistin in the
treatment of P. aeruginosa infection
The design and baseline demographics relating to the
European TOBI trial are presented by Hodson et al.
elsewhere (this supplement and Ref. w31x). This paper
will focus on the microbiological aspects of the trial.
Bacterial culture, storage, and susceptibility testing
(microbroth dilution) were designed to replicate those
used in the US trials of intermittent inhaled tobramycin
in patients with CF w32,33x.
MIC values based on laboratory identification of
different colonial morphotypes were developed from a
previously described scheme w34x. In an attempt to deal
with the heterogeneity of the P. aeruginosa population
discussed earlier, two MIC values were calculated.
Firstly, the highest MIC value observed when represen-
tatives of each colonial morphotype were examined (the
maximum MIC), and secondly, the MIC value obtained
from the colonial morphotype, which represented the
majority of the P. aeruginosa population (the maximum-
density MIC).
1.2. Baseline demographics
P. aeruginosa demographics at the start of the trial
are outlined in Table 2. These data confirm that the
target populations for the two treatment groups are
comparable. Namely, 20 (39%) of the TNS-treated
patients harboured P. aeruginosa, with the highest MIC
values exceeding the resistance breakpoint of 4 mg l ;y1
similarly, 19 (32%) of the colistin-treated patients were
infected by organisms, with the highest MIC of colistin
greater than 4 mg l .y1
1.3. Change in MIC values
Comparative analysis of MICs at the start and end of
therapy indicated that patients whose highest tobramycin
MIC exceeded 4 mg l rose in the TNS-treated patientsy1
from 38 to 49%, but remained at 55% in those treated
with colistin (Table 3). In patients treated with colistin,
colistin MICs above 4 mg l remained stable at 34%;y1
interestingly, tobramycin MICs reduced from 27 to 16%
(Table 4).
1.4. MIC value and clinical response
Fig. 1a,b present the data from individual patients,
plotting the mean relative change in lung function
(FEV % predicted) against the baseline maximum MIC1
of tobramycin (Fig. 1a), and the maximum density
tobramycin MIC value at baseline (Fig. 1b). In both
MIC assessments, clinical change during treatment is
not predicted by the MIC values at baseline. When the
results for colistin MICs at baseline were plotted against
clinical outcome, a similar outcome was revealed: name-
ly, colistin MIC at baseline did not predict clinical
outcome (data not shown).
1.5. 28-Day change in P. aeruginosa log CFU mly110
(intent-to-treat patients)
The sputum density of P. aeruginosa (log CFU)10
during 28-day treatment with tobramycin or colistin was
reduced by 0.9 and 0.6, respectively. The differences
were not significant and may primarily reflect killing of
planktonic forms of P. aeruginosa existing outside the
protection of the biofilm.
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Fig. 1. FEV % response by baseline MIC: (a) Maximum tobramycin MIC; (b) Maximum density tobramycin MIC.1
1.6. Superinfection with B. cepacia and other inherently
resistant pathogens
There was no emergence of B. cepacia or increased
isolation of other inherently resistant Gram-negative
pathogens, including Stenotrophomonas maltophila and
Alcaligenes xylosoxidans, during the 4 weeks of inhaled
tobramycin or colistin. There was a small increase in
the prevalence of Aspergillus species, but this was not
reflected in an increased reporting of acute bronchopul-
monary aspergillosis. Of significance, isolation of B.
cepacia did not increase over an extended treatment
with inhaled tobramycin in ongoing North American
trials w35x.
2. Discussion
The observation that clinical and bacteriological
response to tobramycin and colistin is independent of
MIC value at the start of therapy is not novel; similar
results have been observed in relation to the use of
tobramycin in combination with azlocillin w36x and
tobramycin with azlocillin and timentin w37x. It is also
well known that frequent use of antibiotics to treat
chronic P. aeruginosa increases the risk of bacterial
resistance, reinforcing the need for regular and expert
microbiological monitoring w27,38x. However, resistance
is not synonymous with a worse prognosis, even in
those CF patients who receive a transplant w39,40x, and
it has to be balanced with the benefits of aggressive
therapy in a situation where, if untreated, lung disease
is relentlessly progressive. The microbiological reasons
behind this apparent anomaly are complex and are
discussed under the headings given below.
2.1. Heterogeneity of the pseudomonas population
As discussed earlier, the P. aeruginosa population
present in CF airways is phenotypically heterogeneous,
and this includes heterogeneity in MIC values at the
beginning and end of therapy w14,29,30x. Underlying
this heterogeneity are bacterial factors, such as the
influence of chromosomal loci regulating antibiotic
hypersusceptibility w41x, different muc alleles controlling
alginate biosynthesis w3x, differences in alginate acetyl
content and uronic acid block structure w20x and lipo-
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polysaccharide chemotype (ranging from smooth to
rough 0-antigen deficient) w3x. Associated with, but not
dependent on, these phenotypes are at least five colonial
morphotypes of P. aeruginosa. Heterogeneity in P.
aeruginosa also occurs in non-CF infections, but is best
exemplified in the life-long infections encountered in
the CF lung. In the European TOBI trial, the use of the
highest MIC and highest-density MIC values was a
novel attempt to address the problem of heterogeneity;
however, at best these measurements are a compromise,
with the diversity of the large bacterial population
(around 10 ml ) remaining virtually unmeasurable.8 y1
2.2. Virulence attenuation of resistant organisms
Mechanisms involved in decreasing bacterial suscep-
tibility to antibiotics, either permanently or transiently,
include changes in the antibiotic target, production of
antibiotic inactivating agents, and reduced uptake of the
antimicrobial agent or impermeability. Reduced perme-
ability, which has been shown to be the major mecha-
nism responsible for reduced susceptibility to inhaled
tobramycin w42x, is typically adaptive or transient w43x.
Such resistant organisms are deficient in the production
of extracellular virulence determinants w22x and are
attenuated in vivo w44x.
2.3. Virulence attenuation at sub MIC concentrations
During most of the antibiotic era, the therapeutic
benefits of antibiotics have focused on their ability to
eliminate infectious disease by killing or inhibiting the
growth of bacterial pathogens. It has long been recog-
nized, however, that subinhibitory concentrations of
antibiotics can suppress bacterial virulence w45x. Anti-
biotic-induced suppression of virulence is particularly
relevant to CF lung disease where, with the exception
of aerosol delivery, even the most potent antipseudo-
monal agents seldom reach MIC values and, at the site
of infection, the bacteria are protected by biofilms,
bronchial abscesses, and inflammatory exudates w2,23x.
Aminoglycosides at subinhibitory concentrations
inhibit production of iron-chelating siderophores w46x,
in a manner similar to the suppression of bacterial
proteases by ceftazidime and ciprofloxacin w14,22,47x.
These effects are strain dependent and are independent
of MIC values w22x. Most antibiotics have been found
to inhibit adherence of P. aeruginosa to CF tracheal
cells at subinhibitory concentrations w48x. Tobramycin
and ciprofloxacin at sub MIC concentrations reduce
alginate biosynthesis, arguably the most important bac-
terial virulence factor in CF airways. Indeed, when
measured at the level of transcription using reporter
genes, antibiotics reduce alginate biosynthesis in mucoid
P. aeruginosa at concentrations as low as 5% of the
MIC w7x.
2.4. Aerosol delivery provides high concentrations of
antibiotic in the lung
A final consideration in the interpretation of the
European TOBI trial is the difficulty in defining ‘bac-
terial resistance’, when definitions have previously been
based on non-inhaled administration. Based on parenter-
al administration, breakpoints of tobramycin and colistin
have been set at 4 mg l . However, aerosol deliveryy1
can provide concentrations 100-fold higher than system-
ic concentrations w32x; thus, for inhaled antibiotics, new
breakpoints for resistance seem appropriate. At present,
too few patients harbouring ‘resistant’ P. aeruginosa
have been examined to define such a breakpoint. Such
a redefinition must also reflect the antibiotic-binding
capacity of sputum. Since in vitro studies have shown
that tobramycin concentrations of approximately 10
times the MIC of the bacteria are required to inhibit the
growth of P. aeruginosa in sputum, a level of resistance
for aerosol delivery of tobramycin may be
)128 mg l w33x.y1
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